NCT04142619: Phase 1 - UCART Targeting CS1 - allogenic T cells with anti- CS1 CAR - RRMM (MELANI-01)

(MELANI-01)

Allogenic T cells with anti- CS1 CAR

NCT04142619: Phase 1 - Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity of UCARTCS1A and to determine the Maximum Tolerated Dose (MTD).

Sponsor

Cellectis S.A.

---

ClinicalTrials.gov Identifier: NCT04142619

Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma

First Posted : October 29, 2019

Click here for details on ClinicalTrials.gov

---

UCARTCS1A

Biological: UCARTCS1A

Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor

allogeneic gene-edited CAR T cells UCARTCS1A

allogeneic TALEN gene-edited CAR T cells UCARTCS1A

allogenic engineered T cells expressing anti- CS1 CAR UCARTCS1A

UCARTCS1A cells

---

- California: University of California San Francisco

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Hackensack University Medical Center

- New York: New York Presbyterian / Weill Cornell Medical College New York

- Texas: The University of Texas MD Anderson Cancer Center Houston

---

Locations

United States, California

United States, Minnesota

United States, New Jersey

United States, New York

United States, Texas